Fitbit and app aim to catch immunotherapy side effects early

NCT ID NCT07280715

Recruiting now Symptom relief Sponsor: University of Pittsburgh Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 05, 2026 · Updated 6 times

Summary

This study tests whether a digital tool combining weekly symptom surveys and a Fitbit can help monitor patients during immunotherapy for advanced melanoma. Forty participants will be randomly assigned to use the tool or receive usual care. The goal is to see if the system is easy to use and improves symptom management and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Digital remote monitoring tool (symptom surveys and Fitbit)
What this could lead to: If successful, this approach could help patients manage immunotherapy side effects better and stay connected with their care team.
What could go wrong: This is a small, early feasibility study with only 40 participants, so results may not apply widely. The intervention is behavioral, not a treatment for cancer itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer melanoma metastatic melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER IMMUNOTHERAPY MELANOMA (SKIN CANCER)

Contacts and locations

Locations

UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.